Japan’s Takeda Pharmaceutical said on Friday it will fully cooperate with European regulators who are considering whether its diabetes drug Actos should remain on the market due to a possible link to bladder cancer.The European Medicines Agency (EMA), which had been due to give its decision this week, decided on Thursday to put back a decision until July, saying there were “still numerous issues that needed to be resolved” before it can make a recommendation on the drug’s future use. Takeda said in a statement it would fully cooperate with the agency and submit all available data for its review. “We are confident of the therapeutic benefits and its importance as a type 2 diabetes treatment,” Takeda said in the emailed statement.
